Menu
Recruiting NCT07621783

Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context

— Observational Crohn Disease (CD) Ulcerative Colitis (UC)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Leucine-rich α2-glycoprotein.
Who it may be relevant to
Registry conditions: Crohn Disease (CD), Ulcerative Colitis (UC). Basic parameters: from 16 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Belgium
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context: LEADER Trial.

Overview

Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.

Interventions

  • Diagnostic test Leucine-rich α2-glycoprotein
    Leucine-rich α2-glycoprotein measurement

Primary outcome measures

  • Correlation between LRG serum level and endoscopic disease activity in CD and UC [Time frame: Day 1]

Eligibility criteria

Inclusion criteria

  • ≥18 years
  • Patient with confirmed diagnosis of IBD
  • Patient with planned endoscopy (ileocolonoscopy for Crohn's disease (CD)/ulcerative colitis (UC) or sigmoidoscopy for UC) for the assessment of endoscopic disease activity according to routine practice
  • willing to provide informed consent

Exclusion criteria

  • Patient with IBD unspecified
  • Patient with ileo- or colostomy
  • Patient with total colectomy
  • Women that are pregnant

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Belgium · 1 center
  • Imelda General Hospital — Bonheiden

Identifiers

NCT: NCT07621783 · imelda202601

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗